<DOC>
	<DOCNO>NCT00551317</DOCNO>
	<brief_summary>This study conduct provide initial safety , tolerability , PK PD data allow study darapladib Japanese patient</brief_summary>
	<brief_title>A Study Investigating Concentrations Darapladib Blood Safety This Compound Healthy Japanese Men</brief_title>
	<detailed_description />
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Darapladib</mesh_term>
	<criteria>Inclusion criterion : Japanese male , 2064 year age , inclusive Body weight &gt; 50Kg Body Mass Index ( BMI ) : 1828 Subjects must live outside Japan 10 year Nonsmoker smoke few 10 cigarettes/day Exclusion criterion : History asthma , anaphylaxis anaphylactoid reaction , severe allergic response History sensitivity heparin heparininduced thrombocytopenia History alcohol/drug abuse dependence within 12 month study Positive syphilis , HIV antibody , Hepatitis B , Hepatitis C History cholecystectomy biliary tract disease history liver disease Participation clinical study within 30 day prior first dose Subject expose 4 chemical entity within 12 month Positive urine drug alcohol screen Subject medical history clinically relevant abnormality would make subject ineligible inclusion due safety reason .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>SB480848 ,</keyword>
	<keyword>Japanese healthy volunteer</keyword>
	<keyword>darapladib ,</keyword>
</DOC>